Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: Analysis of a US electronic medical record database

Current Medical Research and Opinion

Volumn 26, Issue 7, 2010, Pages 1697-1703

  Zhang, Qiaoyi ^a   Rajagopalan, Srini ^b   Mavros, Panagiotis ^a   Engel, Samuel S ^a   Davies, Michael J ^a   Yin, Donald ^a   Radican, Larry ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Med Data Analytics Inc   (United States)

Author keywords

Antihyperglycemic therapy; DPP 4; Incretins; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG DOSE REGIMEN; ELECTRONIC MEDICAL RECORD; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHYSICIAN; PRESCRIPTION; UNITED STATES; AGED; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; EVALUATION STUDY; FACTUAL DATABASE; HYPERGLYCEMIA; INDIVIDUALITY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ELECTRONIC HEALTH RECORDS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALITY; MIDDLE AGED; PYRAZINES; RETROSPECTIVE STUDIES; TRIAZOLES; UNITED STATES;

EID: 77953593645     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.489029     Document Type: Article

References (24)

1. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-496
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
3. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-4619
4. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475-1480
5. Vella A, Bock G, Giesler PD, et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) 2008;69:737-744
6. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008;8:14
7. Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
8. Dodd AH, Colby MS, Boye KS, et al. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opin 2009;25:1605-1613
9. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372
10. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
11. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
12. Krentz A. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications. Diabetes Metab Res Rev 2009;25:112-126
13. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-399
14. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9:194-205
15. Aschner P, Katzeff H, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-261
16. Cohen FJ, Neslusan CA, Conklin JE, et al. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003;26:1847-1851
17. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 2007;29:316-325
18. Tong PC, Ko GT, So WY, et al. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 2008;82:346-352
19. Lage MJ, Fabunmi R, Boye KS, et al. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther 2009;26:217-229
20. Radican L, Rajagopalan S, Mavros P, et al. Differences in baseline characteristics between patients on sitagliptin versus exenatide (abstract). Diabetes 2009;58(Suppl. 1):A576
21. Product Information. JANUVIA (sitagliptin). Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 02/2010
22. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-555
23. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007;49:S12-154
24. Lobo FS, Wagner S, Gross CR, et al. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm 2006;2:143-151